Company profile
Home | Diurnal | Dedicated to developing hormone therapeutics
Diurnal is a European, UK-headquartered specialty pharmaceutical company dedicated to developing lifelong treatments for rare and chronic endocrine conditions.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
PSC05 | Transaction MzQ0MDMxOTcyN2FkaXF6a2N4
Published 21 Oct 2024 02:59
CERTNM | Transaction MzQ0MDMxMjM0MWFkaXF6a2N4
Published 21 Oct 2024 02:05
AD03 | Transaction MzQzNzkzOTgzN2FkaXF6a2N4
Published 01 Oct 2024 10:22
AD02 | Transaction MzQzNzY5NTI2OWFkaXF6a2N4
Published 01 Oct 2024 09:11
CS01 | Transaction MzQzNzUwNzIyMWFkaXF6a2N4
Published 27 Sep 2024 10:36
CH01 | Transaction MzQzNzE4NzI3MmFkaXF6a2N4
Published 25 Sep 2024 11:47
Company registered at Companies House
1 Jan 2021 to 31 Dec 2023
This project aims to develop, validate and introduce new salivary tests into the NHS (and worldwide) to simplify the diagnosis and treatment of patients with adrenal insufficiency. The adrenal produces the essential stress hormone cortisol without which patients die from circulatory collapse in what is called an adrenal crisis. Adrenal insufficiency may b...
